Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma M Keyaerts, C Xavier, J Heemskerk, N Devoogdt, H Everaert, C Ackaert, ... Journal of Nuclear Medicine 57 (1), 27-33, 2016 | 383 | 2016 |
Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT LOT Gainkam, L Huang, V Caveliers, M Keyaerts, S Hernot, I Vaneycken, ... Journal of Nuclear Medicine 49 (5), 788-795, 2008 | 271 | 2008 |
SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression L Huang, LOT Gainkam, V Caveliers, C Vanhove, M Keyaerts, ... Molecular Imaging and Biology 10 (3), 167-175, 2008 | 236 | 2008 |
Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer C Xavier, I Vaneycken, M D'huyvetter, J Heemskerk, M Keyaerts, C Vincke, ... J Nucl Med 54 (5), 776-84, 2013 | 225 | 2013 |
HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7 K Breckpot, D Escors, F Arce, L Lopes, K Karwacz, S Van Lint, M Keyaerts, ... Journal of virology 84 (11), 5627-5636, 2010 | 161 | 2010 |
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle Y Dekempeneer, M Keyaerts, A Krasniqi, J Puttemans, S Muyldermans, ... Expert opinion on biological therapy 16 (8), 1035-1047, 2016 | 152 | 2016 |
Same-day imaging using small proteins: clinical experience and translational prospects in oncology A Krasniqi, M D’Huyvetter, N Devoogdt, FY Frejd, J Sörensen, A Orlova, ... Journal of Nuclear Medicine 59 (6), 885-891, 2018 | 123 | 2018 |
Immunogenicity Risk Profile of Nanobodies C Ackaert, N Smiejkowska, C Xavier, YGJ Sterckx, S Denies, B Stijlemans, ... Frontiers in immunology 12, 578, 2021 | 110 | 2021 |
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers K Broos, M Keyaerts, Q Lecocq, D Renmans, T Nguyen, D Escors, ... Oncotarget 8 (26), 41932, 2017 | 108 | 2017 |
Bioluminescence imaging: looking beyond the light M Keyaerts, V Caveliers, T Lahoutte Trends in molecular medicine 18 (3), 164-172, 2012 | 108 | 2012 |
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy T Seremet, Y Jansen, S Planken, H Njimi, M Delaunoy, H El Housni, ... Journal of translational medicine 17 (1), 1-13, 2019 | 107 | 2019 |
Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D-luciferin: effect on intensity, time kinetics and repeatability of … M Keyaerts, J Verschueren, TJ Bos, LO Tchouate-Gainkam, C Peleman, ... European journal of nuclear medicine and molecular imaging 35 (5), 999-1007, 2008 | 107 | 2008 |
The next-generation immune checkpoint LAG-3 and its therapeutic potential in oncology: Third time’sa charm Q Lecocq, M Keyaerts, N Devoogdt, K Breckpot International journal of molecular sciences 22 (1), 75, 2020 | 105 | 2020 |
Noninvasive imaging of the PD-1: PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy K Broos, Q Lecocq, G Raes, N Devoogdt, M Keyaerts, K Breckpot Theranostics 8 (13), 3559, 2018 | 104 | 2018 |
Theranostics in immuno-oncology using nanobody derivatives Q Lecocq, Y De Vlaeminck, H Hanssens, M D'Huyvetter, G Raes, ... Theranostics 9 (25), 7772, 2019 | 92 | 2019 |
Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages C Xavier, A Blykers, D Laoui, E Bolli, I Vaneyken, J Bridoux, H Baudhuin, ... Molecular imaging and biology 21, 898-906, 2019 | 76 | 2019 |
Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients M D’Huyvetter, J De Vos, V Caveliers, I Vaneycken, J Heemskerk, ... Journal of Nuclear Medicine 62 (8), 1097-1105, 2021 | 73 | 2021 |
Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy LOT Gainkam, M Keyaerts, V Caveliers, N Devoogdt, C Vanhove, ... Molecular Imaging and Biology 13 (5), 940-948, 2011 | 68 | 2011 |
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent K Broos, Q Lecocq, C Xavier, J Bridoux, TT Nguyen, J Corthals, ... Cancers 11 (6), 872, 2019 | 59 | 2019 |
Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imaging M Keyaerts, I Remory, V Caveliers, K Breckpot, TJ Bos, J Poelaert, ... PloS one 7 (1), e30061, 2012 | 56 | 2012 |